A study assessing upifitamab rilsodotin (UpRi) for non-small cell lung carcinoma adenocarcinoma
Latest Information Update: 16 Mar 2021
Price :
$35 *
At a glance
- Drugs Upifitamab rilsodotin (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Proof of concept; Therapeutic Use
- Sponsors Mersana Therapeutics
- 16 Mar 2021 New trial record